ArticleAdvances in radiation oncology2026
Utilizing Immune Hormesis Level (IHL) as an Evaluation Tool for Immuno-activation Effects in Photon Lattice Therapies.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiation dose and immune responses elicited by radiation therapy, particularly in Lattice therapy for large-volume tumors, represent an emerging therapeutic strategy. This study investigates the mechanisms of radiation-induced antitumor immunity and introduces the immune hormesis level (IHL) as a novel evaluation metric to replace the traditional peak-to-valley dose ratio. Unlike the peak-to-valley dose ratio, IHL standardizes dose distribution into a 0% to 100% scale by quantifying differences between peak and valley doses across isodose curves, providing a more objective and comparative indicator of immunogenic potential. Within the gross tumor volume, high-dose regions induce direct cytotoxicity and dendritic cell activation, whereas low-dose regions preserve vasculature and lymphatic drainage, enhancing both bystander and abscopal effects. Nine clinically relevant photon-based intensity modulated radiation therapy and Arc therapy (or Volumetric Modulated Arc Therapy) treatment modalities were designed and evaluated using IHL, with dose vertex size determined by photon scattering to ensure uniformity. We further derived a functional relationship between dose-sphere diameter and optimal spacing, offering a quantitative solution for tailoring Lattice therapy to tumor size. This approach provides a framework for optimizing spatial dose distributions to maximize immune stimulation, representing the most innovative contribution of this study.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.